Novo Nordisk debuts Wegovy weight-loss pill in the U.S.
CBS News••business
Key Points:
- Novo Nordisk has launched an oral pill version of its weight-loss drug Wegovy in the U.S., offering a new convenient option for obesity treatment.
- The starting dose of the Wegovy pill is 1.5 mg, priced at $149 per month for self-paying patients, with a 4 mg dose available at the same price until April 15 before increasing to $199.
- The FDA approved the Wegovy pill in December, making it the first and only GLP-1 pill for weight loss, containing 25 mg of semaglutide, the same active ingredient as the injectable versions.
- Side effects of the pill are similar to the injectable form, including nausea and diarrhea, according to Novo Nordisk
